Switch theme
Sign up to access all valuation multiples
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company’s flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
2021
26
LTM Revenue $1.1M
Last FY EBITDA -$19.6M
$4.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mainz Biomed has a last 12-month revenue (LTM) of $1.1M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Mainz Biomed achieved revenue of $0.9M and an EBITDA of -$19.6M.
Mainz Biomed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mainz Biomed valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1M | XXX | $0.9M | XXX | XXX | XXX |
| Gross Profit | $1.1M | XXX | $0.6M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 64% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$19.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -2188% | XXX | XXX | XXX |
| EBIT | n/a | XXX | -$18.4M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | -2060% | XXX | XXX | XXX |
| Net Profit | n/a | XXX | -$21.7M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | -2422% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Mainz Biomed's stock price is $2.
Mainz Biomed has current market cap of $7.6M, and EV of $4.7M.
See Mainz Biomed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.7M | $7.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Mainz Biomed has market cap of $7.6M and EV of $4.7M.
Mainz Biomed's trades at 5.2x EV/Revenue multiple, and -0.2x EV/EBITDA.
Equity research analysts estimate Mainz Biomed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mainz Biomed's P/E ratio is not available.
See valuation multiples for Mainz Biomed and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.6M | XXX | $7.6M | XXX | XXX | XXX |
| EV (current) | $4.7M | XXX | $4.7M | XXX | XXX | XXX |
| EV/Revenue | 4.3x | XXX | 5.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.2x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -0.3x | XXX | XXX | XXX |
| EV/Gross Profit | 4.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMainz Biomed's last 12 month revenue growth is 5%
Mainz Biomed's revenue per employee in the last FY averaged $34K, while opex per employee averaged $0.7M for the same period.
Mainz Biomed's rule of 40 is -2744% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mainz Biomed's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Mainz Biomed and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -2188% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -2744% | XXX | -2183% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $34K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 525% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 653% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2125% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mainz Biomed acquired XXX companies to date.
Last acquisition by Mainz Biomed was XXXXXXXX, XXXXX XXXXX XXXXXX . Mainz Biomed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Mainz Biomed founded? | Mainz Biomed was founded in 2021. |
| Where is Mainz Biomed headquartered? | Mainz Biomed is headquartered in United States of America. |
| How many employees does Mainz Biomed have? | As of today, Mainz Biomed has 26 employees. |
| Who is the CEO of Mainz Biomed? | Mainz Biomed's CEO is Mr. Guido Baechler. |
| Is Mainz Biomed publicy listed? | Yes, Mainz Biomed is a public company listed on NAS. |
| What is the stock symbol of Mainz Biomed? | Mainz Biomed trades under MYNZ ticker. |
| When did Mainz Biomed go public? | Mainz Biomed went public in 2021. |
| Who are competitors of Mainz Biomed? | Similar companies to Mainz Biomed include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Mainz Biomed? | Mainz Biomed's current market cap is $7.6M |
| What is the current revenue of Mainz Biomed? | Mainz Biomed's last 12 months revenue is $1.1M. |
| What is the current revenue growth of Mainz Biomed? | Mainz Biomed revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Mainz Biomed? | Current revenue multiple of Mainz Biomed is 4.3x. |
| Is Mainz Biomed profitable? | Yes, Mainz Biomed is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
